Search

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Read more

Be part of the EHA community

How you can take an active role and help drive EHA's direction. As a membership organization, EHA is dependent on the dedication of its board and committee members.

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

6th European CAR T-cell Meeting

Dates: February 15-17, 2024
Location: Valencia, Spain
Format: Hybrid
Chairs: Michael Hudecek & Anna Sureda

Registration is closed. Those already registratered can view on-demand content via the platform until March 17.

Read more